High grade, synchronous colon cancers after renal transplantation: were immunosuppressive drugs to blame?

Trivedi, Madhuri

doi:10.1016/s0002-9270(99)00612-7

Cited by 8 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous explanations for an increased adenoma‐carcinoma sequence in SOT patients include impairment of immune surveillance, increased susceptibility to potentially oncogenic viruses (i.e. Epstein–Barr Virus or [Polyoma] JC virus), chronic stimulation of the lymphoreticular system, or neoplastic effects of immune suppression medications [10,11].…”

Section: Discussionmentioning

confidence: 99%

Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study

Spier

Walker

Cornett

et al. 2010

Transplant International

View full text Add to dashboard Cite

Summary The aim of this study was to evaluate the detection of colonic neoplasia in an average‐risk population of SOT recipients. Studies regarding colonic neoplasia in solid organ transplantation (SOT) recipients have demonstrated mixed results due to the inclusion of above average‐risk patients. We performed a case–control study of 102 average‐risk SOT recipients who underwent screening colonoscopy, compared with an average‐risk, age and sex‐matched control group (n = 287). Cancer rates were compared with an age‐matched cohort from the National Cancer Institute’s Survival, Epidemiology, and End Results (SEER) database. There was no difference in number of patients with adenomas (P = 1.00). There was no difference in polyps per patient (P = 0.31). Although the number of advanced lesions (excluding adenocarcinoma) between groups did not differ (P = 0.25), there were two adenocarcinomas identified in the SOT group and none in the control group (P = 0.068). Detection of colorectal cancer was an unexpected finding in the SOT cohort and was more likely when compared to age‐matched cancer incidence generated by the SEER database. These results suggest no increased adenoma detection in SOT recipients, but with more cases of colorectal cancer than anticipated. Given previous, larger, transplant database studies demonstrating increased colorectal cancer rates, more frequent screening may be justified.

show abstract

Section: Discussionmentioning

confidence: 99%

Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study

Spier

Walker

Cornett

et al. 2010

Transplant International

View full text Add to dashboard Cite

show abstract

“…A significant overall increase of colon cancer was reported after renal grafts in Australia and New Zealand and the Nordic countries [7,8]. Further studies support the notion of an increased risk of colon cancer but not rectal cancer after renal transplantation [9–11].…”

Section: Introductionmentioning

confidence: 99%

Colorectal cancer in patients with chronic renal failure: the effect of dialysis or renal transplantation

Russ

Stephens

et al. 2002

Colorectal Disease

View full text Add to dashboard Cite

OBJECTIVE: This study reports the characteristics and surgical outcome of colorectal cancer in patients with chronic renal failure treated either by renal transplantation or dialysis. METHODS: Two thousand four hundred and seventeen patients with CRF (1387 transplant and 1030 dialysis) were treated at The Queen Elizabeth Hospital, South Australia, between January 1967 and September 2000. RESULTS: Fourteen have developed colorectal cancer and had their clinical records reviewed. Nine patients were renal transplant recipients and 5 patients were treated with dialysis. Eight patients had surgery. Chemotherapy was given palliatively to 3 patients. One patient died in hospital postoperatively. Seven patients with a renal transplant had notes available. Six presented with late stage disease and all were dead within 9 months of presentation from their disease. In the dialysis patients, tumour stage at presentation was not so advanced and although all the patients have died, the cause of death was secondary to the colorectal cancer in only 2 patients. CONCLUSIONS: This study highlights the poor outcome of patients who have had renal transplant and develop colorectal cancer. Immunosuppression and late diagnosis are implicated in this poor outcome.

show abstract

“…This is primarily a consequence of the immunosuppressive drug regimens necessary to prevent rejection. 1 Malignancies in the posttransplantation period can be caused by infections with oncogenic viruses (such as posttransplantation lymphoproliferative disorders caused by the Epstein-Barr virus), recurrence of primary cancers in the recipients and occult malignancies not diagnosed before transplantation, donor-transmitted malignancies (known, occult, or missed), and de novo malignancies. Although transplant recipients are at increased risks for development of many different types of cancers, skin cancers and non-Hodgkin lymphomas are the most prevalent entities.…”

Section: Introductionmentioning

confidence: 99%

Incidence and Management of Colorectal Cancer in Liver Transplant Recipients

Nishihori

Strazzabosco

Saif

2008

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Liver transplant recipients are at an increased risk of developing de novo malignancies because of the prolonged immunosuppression necessary to avoid acute and chronic rejections. Skin cancers and lymphoproliferative diseases are the most common malignancies, but the overall incidence of colon cancer in this patient population does differ from that of the general population. Therefore, colorectal cancer (CRC) is a major health concern in liver transplant recipients. Furthermore, there are unique subsets of liver transplant recipients, such as those with primary sclerosing cholangitis and inflammatory bowel disease, who are at an increased risk for developing CRC after liver transplantation and might require special screening/surveillance strategies. The similar principles for management of colon cancer can be applied to transplant recipients if the adjustment to maintain the need for the long-term immunosuppression is made. Colectomy can be performed safely during the posttransplantation period. Prophylactic colectomy at the time of liver transplantation has been performed in some patients at high risk or with known premalignant conditions. Chemotherapy with 5-fluorouracil and oxaliplatin has been used in transplant recipients for the treatment of metastatic CRC; however, further research is required to examine the safety, tolerability, and efficacy of combination chemotherapy and biologic agents in this patient population. This review summarizes the incidence, risk factors, diagnosis, and management of de novo CRC in liver transplant recipients.

show abstract

High grade, synchronous colon cancers after renal transplantation: were immunosuppressive drugs to blame?

Cited by 8 publications

References 0 publications

Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study

Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study

Colorectal cancer in patients with chronic renal failure: the effect of dialysis or renal transplantation

Incidence and Management of Colorectal Cancer in Liver Transplant Recipients

Contact Info

Product

Resources

About